Skip to main content
. Author manuscript; available in PMC: 2018 Nov 14.
Published in final edited form as: Cancer Res. 2018 May 2;78(13):3672–3687. doi: 10.1158/0008-5472.CAN-17-3167

Figure 7: Responses in AKT signaling following MET and MEK inhibition of NF1-MET, NF1-P53, and NF1 MPNSTs.

Figure 7:

(A) Immunostaining of pAKT (S473) in MPNST models that were treated with kinase inhibitors for 2 days (areas of strongest signal are shown in the magnified inset boxes). (B-D) Western Blot analysis of MPNST cells treated with TKIs for 2 hours and +/− HGF for pAKT (left panels), total AKT (middle panels), and β-tubulin control (right panels).